| Jewel Swanson, PLMHP | |
|
221 W Douglas St, Oneill, NE 68763 | |
| (402) 336-2800 | |
| (402) 336-2849 |
| Full Name | Jewel Swanson |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 221 W Douglas St, Oneill, Nebraska |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447739040 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | 11575 (Nebraska) | Primary |
| Entity Name | Heartland Counseling Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033292784 PECOS PAC ID: 0749262509 Enrollment ID: O20040604000284 |
News Archive
The Critical Path Institute (C-Path) today announced that its Type 1 Diabetes (T1D) Consortium has received a letter of support from the European Medicines Agency (EMA) to facilitate the development and validation of the proposed regulatory qualification of pancreatic islet autoantibodies commonly used in clinical practice to diagnose T1D: insulin autoantibodies, glutamic acid decarboxylase 65, and insulinoma antigen-2 autoantibodies as enrichment biomarkers for T1D clinical trials.
Optimer Pharmaceuticals, Inc. announced today the presentation of combined data from its two fidaxomicin Phase 3 trials in patients with Clostridium difficile infection (CDI) at the 48th Annual Meeting of the Infectious Disease Society of America (IDSA) in Vancouver, British Columbia, Canada.
Kaiser Health News staff writer Julie Appleby reports: "One of the nation's largest health insurers said today it is testing a new way to pay for some cancer treatments, aiming to identify the best medicines - and limit profits doctors make by dispensing in-office chemotherapy drugs" (Appleby, 10/20).
Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jewel Swanson, PLMHP Po Box 355, South Sioux City, NE 68776-0355 Ph: (402) 494-3337 | Jewel Swanson, PLMHP 221 W Douglas St, Oneill, NE 68763 Ph: (402) 336-2800 |
News Archive
The Critical Path Institute (C-Path) today announced that its Type 1 Diabetes (T1D) Consortium has received a letter of support from the European Medicines Agency (EMA) to facilitate the development and validation of the proposed regulatory qualification of pancreatic islet autoantibodies commonly used in clinical practice to diagnose T1D: insulin autoantibodies, glutamic acid decarboxylase 65, and insulinoma antigen-2 autoantibodies as enrichment biomarkers for T1D clinical trials.
Optimer Pharmaceuticals, Inc. announced today the presentation of combined data from its two fidaxomicin Phase 3 trials in patients with Clostridium difficile infection (CDI) at the 48th Annual Meeting of the Infectious Disease Society of America (IDSA) in Vancouver, British Columbia, Canada.
Kaiser Health News staff writer Julie Appleby reports: "One of the nation's largest health insurers said today it is testing a new way to pay for some cancer treatments, aiming to identify the best medicines - and limit profits doctors make by dispensing in-office chemotherapy drugs" (Appleby, 10/20).
Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.
› Verified 8 days ago
Julie Lingenfelter, LIMHP Counselor Medicare: Not Enrolled in Medicare Practice Location: 118 N 5th St, Oneill, NE 68763 Phone: 402-336-4841 Fax: 402-336-4640 | |
Ms. Jessica A Clark, MSW Counselor Medicare: Medicare Enrolled Practice Location: 300 N 2nd St Ste 100, Oneill, NE 68763 Phone: 402-336-2947 | |
Brenda Nelson, Counselor Medicare: Not Enrolled in Medicare Practice Location: 118 N 5th St, Oneill, NE 68763 Phone: 402-336-4841 Fax: 402-336-4640 | |
Lindsey Ondrak, Counselor Medicare: Not Enrolled in Medicare Practice Location: 118 N 5th St, Oneill, NE 68763 Phone: 402-336-4841 Fax: 402-336-4841 | |
Mrs. Bonnie L. Hines, LMHP Counselor Medicare: Not Enrolled in Medicare Practice Location: 118 N 5th St, Oneill, NE 68763 Phone: 402-336-4841 Fax: 402-336-4640 | |
Ms. Kathleen M Benson, LADAC Counselor Medicare: Not Enrolled in Medicare Practice Location: 118 N 5th St, Oneill, NE 68763 Phone: 402-336-4841 Fax: 402-336-4640 | |
Michael Dean Williamson, MSE, LIMHP, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 614 N 4th St Ste 108, Oneill, NE 68763 Phone: 402-336-1306 |